Enhanced immunity in a mouse model of malignant glioma is mediated by a therapeutic ketogenic diet.
Level 5 - mechanism / opinion, no new human data
Animal laboratory study (preclinical GL261-Luc2 glioma mouse model).
PubMed 27178315 · doi:10.1186/s12885-016-2337-7
What was done
Researchers used a GL261-Luc2 intracranial mouse model of malignant glioma to evaluate the impact of a therapeutic ketogenic diet on anti-tumor immunity. Flow cytometry was used to quantify tumor-infiltrating CD8+ T cells, CD4+ T cells, natural killer cells, regulatory T cells, and the expression of immune checkpoint receptors CTLA-4 and PD-1. Intracellular cytokine production (including interferon, IL-2, and IL-10) and cytolytic activity were also measured.
What was found
The abstract reports qualitative outcomes without specific numerical values, percentages, or effect sizes. Mice fed the ketogenic diet showed increased innate and adaptive immune responses, characterized by elevated cytokine production and tumor-reactive CD8+ T cell cytolysis. Ketogenic diet feeding also led to increased CD4+ T cell infiltration with stable regulatory T cell numbers, alongside significant reductions in immune inhibitory receptor expression on T cells and inhibitory ligands on glioma cells.
Why it matters
These findings suggest that the ketogenic diet may serve as a metabolic adjuvant capable of reversing local immunosuppression in malignant glioma, providing a mechanistic basis for combining metabolic therapy with immunotherapy.
Limits
The study is restricted to an animal model (syngeneic mouse glioma) and findings cannot be directly extrapolated to human glioblastoma multiforme. The abstract does not provide sample sizes, quantitative metrics, confidence intervals, or statistical values, nor does it evaluate long-term systemic immune safety or clinical outcomes.
Cited by
- supports Research by Dr. Adrienne Scheck showed that combining a dietary intervention with radiation enhanced cancer-specific immune regulation in a glioblastoma cell line.